Tell HN: An inside view of Montana's new biotech law

A new law in Montana, SB535, allows physicians to provide experimental treatments outside of trials, with some conditions. The law requires a state-registered private review board approval, consent exceeding federal standards, and adverse event reporting. Sponsors can charge patients for treatment, which is a key difference from previous laws like Right to Try and Expanded Access. The law also has oversight mechanisms, including safety review and outcome reporting. This could help biotech companies gain real-world data and improve their Phase 2/3 design, potentially reducing the cost of drug development.